HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Schachter, S. C. Articles by Wheless, J. W. Search for Related Content PubMed PubMed Citation Articles by Schachter, S. C. Articles by Wheless, J. W.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

The evolving place of vagus nerve stimulation therapy

From the Department of Neurology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA (Dr. Schachter), and the Departments of Neurology and Pediatrics, University of Texas–Houston and Memorial Hermann Hospital, Houston, TX (Dr. Wheless).

Article Abstract

Article abstract Approximately 40% of patients with epilepsy have seizures that do not adequately respond to medical therapy. Vagus nerve stimulation (VNS) therapy, approved 5 years ago by the Food and Drug Administration, offers a therapeutic option for patients with pharmacoresistant seizures. This supplement updates developments with VNS therapy since its approval and suggests future directions for this still-evolving treatment.